Brief: Cantargia Announces Phase 1 Data Supporting Monthly CAN10 Dosing
12/05/2025 06:35
May 12 (Reuters) - Cantargia AB CANTA.ST: CANTARGIA ANNOUNCES SUCCESSFUL PHASE 1 RESULTS: PK/PD DATA OF SUBCUTANEOUSLY ADMINISTERED CAN10 CONFIRMS EVERY 4-WEEK DOSING CHOICE IN PHASE 2 MODEL CONFIRMS SC DOSING EVERY 4-WEEK FOR PHASE 2 Source text: ID:nMFN5LM93k Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML